Zenas BioPharma shares fell sharply after the company reported favorable Phase 3 study results for obexelimab in immunoglobulin G4-related disease. The stock fell 56% to $15.22. Despite Monday's ...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / November 20, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announces strong topline results from the Phase 3 MANIFEST-2 study investigating pelabresib, an ...
Baxdrostat 2mg lowered systolic blood pressure by 15.7 mmHg (9.8 mmHg placebo-adjusted) from baseline, and was generally well tolerated with no unanticipated safety findings Full results presented at ...
Romosozumab use in adults with osteoporosis was associated with a 21% reduction in risk for osteoarthritis, particularly knee osteoarthritis, compared with teriparatide use. Researchers used a ...
Please provide your email address to receive an email when new articles are posted on . A single burst of antitachycardia pacing (ATP) reduced risk for shocks in patients with an implantable ...
- Acoramidis demonstrated a significant reduction in risk of CVM through 42 months post-randomization, with a 44% hazard reduction, setting a new standard for CVM outcomes for patients with ATTR-CM - ...
Independent Data Monitoring Committee recommended trial stop early due to overwhelming efficacy at pre-planned analysis AstraZeneca’s inhaled anti-inflammatory rescue medication AIRSUPRA demonstrated ...
WILMINGTON, Del.--(BUSINESS WIRE)-- AIRSUPRA’s US Prescribing Information now includes clinically meaningful evidence from the BATURA study in patients with mild asthma. 1 The BATURA Phase IIIb trial, ...
The first trial of a novel strategy for removing cholesterol from patients’ arteries did not reduce the risk of death, heart attack or stroke within three months of a prior heart attack, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback